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Background: DEK, as an oncoprotein, plays an important role in cancer development and progression. This study
aimed to investigate the clinicopathological significance of DEK overexpression in patients with gastric cancer.
Materials and methods: The expression of DEK protein was evaluated by immunohistochemical (IHC) staining of
172 gastric cancer samples with complete clinicopathological features, and the correlation between DEK expression
and clinicopathological features was examined. Survival rates were also calculated using the Kaplan-Meier method
in gastric cancer patients with complete survival data.
Results: DEK protein showed a strictly nuclear staining pattern in gastric cancers with IHC and immunofluorescence.
The strongly positive rate of DEK protein was 60.5% (104/172) in gastric cancers, which was significantly higher than
that in either gastric dysplasia (19.4%, 7/36) or adjacent normal mucosa (0%, 0/27). DEK expression in gastric cancer
correlated to tumor size, differentiation, clinical stage, disease-free survival, and overall survival rates. Further analysis
showed that patients with early-stage gastric cancer and high DEK expression had shorter disease-free survival and
overall survival duration than those with low DEK expression.
Conclusion: High level of DEK protein expression predicts the poor prognosis of patients with gastric cancer. DEK
expression might be potentially used as an independent effective biomarker for prognostic evaluation of gastric cancers.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
5050145571193097
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Gastric cancer is one of the most common cancers
worldwide, and it is the second most common cause of
cancer death [1]. In recent years, development of molecular
drugs and traditional chinese medicine targeting oncogenic
pathways has led to improvement of treatment outcome
in gastric cancer [2]. In addition, the biomarkers for prog-
nostic evaluation of patients with gastric cancers were also
investigated widely. For example, Gao et al. reported that
the expression of E-cadherin and claudin was correlated
with lymphatic metastasis [3]. Geng et al. showed that the
expressions of Pgp, GST-π and Topo II were related with* Correspondence: liyuzi9258@163.com; zhlin720@ybu.edu.cn
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unless otherwise stated.gastric cancer chemosensitivity [4]. Furthermore, Canzonieri
et al. also demonstrated that endocrine differentiation,
maturely exocrine and endocrine gastric phenotypes are
associated with poor prognosis [5]. However, the prognosis
of gastric cancer has not significantly improved. Therefore,
the discovery of novel biomarkers of gastric cancer is
required for early diagnosis and to help provide novel
therapeutic targets.
Human DEK was initially demonstrated to be the target
of a recurrent t(6;9) translocation that generates fusion
with CAN in a subset of acute myeloid leukemia (AML)
patients [6]. It was identified as an oncoprotein and has a
molecular weight of 42Kda. DEK plays an important role
in cell processes and participates in a variety of cellular
metabolic functions, such as global heterochromatin
integrity [7], transcriptional control [8], mRNA splicing
[9], DNA replication [10], DNA damage repair and sus-
ceptibility [11].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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variety of cellular mechanisms are dysregulated in tumor
cells, such as altered expression levels and altered affinity
to DNA, and result in occupancy of promoters and en-
hancers of other genes [12]. For example, Sanchez-Carbayo
et al. reported that DEK was differentially expressed
between the early-stage and invasive clusters of bladder
cancer using cDNA microarrays [13]. Casas et al. detected
DEK expression levels in 41 adult patients with AML
using quantitative real-time PCR, and observed that
DEK was overexpressed in 98% of cases [14]. We also
previously found that DEK was significantly overexpressed
in colorectal cancers and that the expression correlated to
poor prognostic factors with colorectal cancers [15]. These
results suggest that altered expression of DEK is asso-
ciated with several human malignancies. However, the
relationships between DEK expression and gastric cancer
are not clear.
In the present study, we found that the expression of
DEK was upregulated in gastric cancer tissues, and DEK
might be an independent biomarker for the prediction
of gastric cancer prognosis, suggesting that DEK plays




This study complied with the principles of the Declaration
of Helsinki and was approved by the human ethics and
research ethics committees of Yanbian University Medical
College in China. The patients were informed that their
resected specimens were stored by our hospital and
potentially used for scientific research, and that their
privacy would be maintained. Follow-up survival data were
collected retrospectively through medical-record analyses.
Clinical specimens
Routinely diagnosed primary gastric cancer tissues (172
cases) with clinical features were collected from patients
who underwent surgery between February 2002 and May
2004 by Shanghai Outdo Biotech Co. Ltd. (Outdo Biotech)
and Tumor Tissue Bank of Yanbian University Medical
College. Of the 172 cases, 67 were well differentiated, 82
were moderately differentiated, and 23 were poorly differ-
entiated cancers. A pathological stage for each tumor was
assigned using the Union for International Cancer Control
(7th edition) criteria and World Health Organization clas-
sifications (Pathology and Genetics Tumors of the Digest-
ive System) [16]. Total samples comprised 92 cases with
stage 0–II and 80 cases with stage III–IV. Before surgery,
no patients had received chemotherapy or had distant me-
tastases. The follow-up time of the primary gastric cancer
cohort was in the range of 5–8 years. By December 2012,
98 patients had died and 64 patients remained alive.Immunofluorescence (IF) staining for DEK in MKN-1 gastric
cancer cell line
MKN-1 gastric cancer cells grown on coverslips was fixed
with 4% paraformaldehyde in PBS for 10 min at room
temperature and permeabilized with 0.5% TritonX-100 for
10 min. Then washed again with PBS and blocking was
performed with 3% Albumin Bovine V (A8020, Solarbio,
Beijing, China) for one hour at the room temperature
(RT). Primary antibodies against DEK (1:50; BD Biosci-
ences, USA) and β-Tubulin (1:50; Santa Cruz Biotechnol-
ogy, USA) were incubated with cells at 4°C overnight. After
more washes, cells were incubated with Alexa Fluor® 488
Goat Anti-Rabbit IgG (H+C) (A11008, 1:1000, Invitrogen,
USA) and Alexa Fluor® 568 Goat Anti-Mouse IgG (H+ L)
(A11004, 1:1000, Invitrogen, USA) for 1 h. Subsequently,
cells were washing again with PBS and counterstained with
2-(4-Amidinophenyl)-6-indolecarbamidine dihydrochloride
(C1006, Beyotime, China). Coverslips were mounted with
Antifade Mounting Medium (P0126, Beyotime, China) [17].
Finally, the immunofluorescence signals were visualized
and recorded by Leica SP5II confocal microscope.
Immunohistochemistry (IHC) for DEK in paraffin-embedded
tissues
As described previously [15], a Dako LSAB kit (Dako A/S,
Glostrup, Denmark) was used to perform immunohisto-
chemical analysis. Four-micrometer-thick tissue sections
were deparaffinized, rehydrated, and incubated with 3%
H2O2 in methanol. Subsequently, the antigen was retrieved,
followed by incubation with 1% bovine serum albumin.
Slides were then incubated with a DEK antibody (1:50; BD
Biosciences Pharmingen, San Jose, USA) at 4°C overnight.
Normal goat serum was used as the negative control. After
incubation with a secondary antibody at room temperature
for 30 min, slides were incubated with streptavidin-perox-
idase complex. The peroxidase reaction was developed
with 3,3’-diaminobenzidine and counterstained with Mayer’s
hematoxylin. Rabbit IgG isotope was used as a negative
control and positive tissue sections were processed omitting
the primary antibody as a further negative control.
Evaluation of IHC staining
All slides were evaluated independently by two pathologists
without prior knowledge of clinical outcomes. We first
observed staining in the whole gastric lesion, and then
quantified 50 representative fields. Only the nuclear stain-
ing pattern was considered as positive. The immunostain-
ing was scored as ‘−’ (negative, no or less than 5% positive
cells), ‘+’ (5–25% positive cells), ‘++’ (26–50% positive cells)
and ‘+++’ (more than 50% positive cells). The strongly
positive descriptor (DEK overexpression) was assigned
to ‘++’ and ‘+++’ scored cells. For survival analysis, DEK
expression level was denoted as high expression (‘++’ and
‘+++’) and low expression (‘−’ and ‘+’) [15].
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Statistical analyses were conducted using SPSS 17.0. Asso-
ciation between DEK expression and clinicopathological
features were evaluated by Chi-square test and Fisher’s
exact tests. The Kaplan–Meier method was used for ana-
lysis of survival curves, and statistical significance was
assessed using the log-rank test. Multivariate survival
analysis was performed on all significant characteristics
measured by univariate survival analysis (gender, age,
tumor size, differentiation, lymph node metastasis, serosal
invasion, tumor stage, and DEK expression) through the
Cox proportional hazard regression model. A P value <0.05
was considered statistically significant.
Results
DEK protein was overexpressed in gastric cancer
DEK protein showed a strictly nuclear staining pattern
in gastric cancers with IF (Figure 1) and IHC (Figure 2).
The positive rate of DEK protein expression was 70.3%
(121/172) in gastric cancer tissues, which was significantly
higher than that in either gastric dysplasia (41.7%, 15/36)
or normal adjacent mucosa (18.5%, 5/27). Similarly, the
strongly positive rate of DEK protein (60.5%, 104/172) was
also significantly higher than either gastric dysplasia
(19.4%, 7/36) or adjacent normal gastric mucosa (0%,
0/27) (P < 0.01, respectively) (Table 1).Figure 1 Immunofluorescence staining for DEK and β-Tubulin protein
nucleus of MKN-1 gastric cancer cells. (Red for DEK, Green for β-Tubulin, anCorrelation between clinicopathological features and DEK
overexpression
We analyzed the relationship between DEK overexpression
and clinicopathological features of gastric cancers. The
strongly positive rate of DEK expression was significantly
higher in gastric cancers with ≥5 cm tumor size (55/73,
75.3%) than in cases with <5 cm tumor size (49/99 49.5%)
(P < 0.05). Similarly, DEK expression was significantly higher
in poorly differentiated gastric cancers (32/44, 72.7%) than
in moderately (26/47, 55.3%) or well differentiated gastric
cancers (46/81, 56.8%) (P < 0.05).
For TNM clinical staging, we found a strongly positive
rate of DEK expression of 71.3% (57/80) in advanced-stage
(III–IV) gastric cancers, and only 51.1% (47/92) in early-
stage (0–II) cases (P < 0.01). Nevertheless, DEK overexpres-
sion in gastric cancers was not related to age, gender,
Lauren types and serosal invasion (Table 2).
Correlation between DEK overexpression and survival of
patients with gastric cancer
A total 172 patients with gastric cancer were identified
for analysis of prognostic evaluation. Both disease-free
survival and overall survival rates were significantly higher
in gastric cancer patients with low DEK expression than
in those with high DEK expression (Figure 3). Of the 172
gastric cancer patients, 92 were early stage and 80 weres in MKN-1 gastric cancer cells. DEK protein is strictly located at the
d Blue for DAPI).
Figure 2 Immunohistochemical staining of DEK protein in gastric cancer and normal mucosa. A: DEK is negative in normal gastric mucosa.
B: DEK protein is strongly positive in the nucleus of gastric cancer cells with lymph node metastasis. C: DEK protein showed scattered staining
pattern in gastric adenocarcinoma without metastasis. D: DEK is positive in invasive cancer cells around the nerve (arrow) in the serosal layer
(Original magnification, ×200).
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cancer, the survival analysis demonstrated that a DEK
level was associated with lower disease-free and overall
survival rates (P = 0.003 and P = 0.002, respectively, log-
rank) (Figure 4). However, the expression status of DEK
protein did not correlate to survival rate in patients with
advanced stage (III–IV) gastric cancer (P = 0.255 and P =
0.137, respectively, log-rank).
DEK overexpression is an independent prognostic factor in
gastric cancers by Cox proportional hazard regression model
Using univariate analysis, we found that gastric cancer
patients with high DEK expression had significantly
lower disease-free and overall survival rates than those
with low DEK expression tumors. Additionally, serosal






positive rate (%)- + ++ +++
Gastric cancers 172 51 17 67 37 70.3%** 60.5%**
Dysplasia 36 21 8 7 0 41.7%** 19.4%**
Normal 27 22 5 0 0 18.5% 0
**P < 0.01, compared with normal mucosa and dysplasia of gastric. Dysplasia:
gastric dysplasia; Cancer: gastric cancer; Positive rate: percentage of positive
cases with ‘+’, ‘++’, and ‘+++’ staining score; Strongly positive rate: percentage
of positive cases with ‘++’ and ‘+++’ staining score.also associated with disease-free and overall survival rates,
suggesting that DEK could be a valuable prognostic factor
in gastric cancer. Therefore, multivariate analysis was per-
formed using the Cox proportional hazards model for all
significant variables examined in the univariate analysis.
We found that the presence of lymph node metastasis
(hazard ratio (HR): 1.490, 95% confidence interval (CI):
0.091–2.036, P = 0.012) and late stage (HR: 1.837, 95% CI:
1.323–2.551, P = 0.000) proved to be independent poor
prognostic factors for survival in gastric cancer. Import-
antly, high DEK expression also emerged as a significant
independent poor prognostic factor in gastric cancer (HR:
1.422, 95% CI: 1.033–1.956, P = 0.031) (Table 3).
Discussion
The human DEK gene is generally considered a proto-
oncogene because of its involvement in chromosomal
translocation in AML and its upregulation in a variety of
human malignancies [6,18]. To date, accumulating evidence
from studies suggests a correlation between DEK and
several types of human malignancies, such as melanoma
[19], glioblastoma [20], breast cancer [21] and bladder
cancer [22], but little is known about gastric cancers.
This is the first study, to our knowledge, to correlate
DEK levels in GAC with histological prognostic factors
to understand the role of DEK upregulation in gastric
cancer progression. Here we performed IF and IHC
Table 2 Relationship between DEK protein overexpression









<56 96 55 (57.3%)
≥56 76 49 (64.5%)
Gender 0.011 0.918
Male 102 62 (60.8%)
Female 70 42 (60.0%)
Tumor size 10.501 0.001**
≥5 cm 73 55 (75.3%)
<5 cm 99 49 (49.5%)
Serosal invasion 0.283 0.596
Yes 81 46 (56.8%)
No 91 48 (52.7%)
Lauren types 5.581 0.118
Intestinal type 89 47 (52.8%)
Diffuse type 72 51 (70.8%)
Mixed type 11 6 (54.5%)
Differentiation 19.732 0.000**
Well 67 27 (40.3%)
Moderately 82 58 (70.7%)
Poorly 23 19 (82.6%)
LN Metastasis 1.417 0.235
Negative 89 50 (56.2%)
Positive 83 54 (65.1%)
Clinical stage 7.277 0.007**
0-II 92 47 (51.1%)
III-IV 80 57 (71.3%)
**P < 0.01.
Figure 3 Kaplan–Meier analysis of disease-free and overall survival ra
expression. Gastric cancer patients with DEK-positive expression had lowe
DEK-negative expression as determined using the Kaplan–Meier method. (+
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36 of gastric dysplasia and 172 of GAC and their adjacent
normal tissue counterparts. We found that high levels
of DEK expression were associated with poor prognosis
in gastric cancer patients. We also observed that altered
expression levels of DEK protein in gastric cancer tissues,
which were significantly higher than both adjacent noncan-
cerous tissues and normal stomach tissues. Our results sug-
gest the important role of DEK protein in the prognosis of
patients with gastric cancer.
As DEK may be present at higher levels in immature
cells than in differentiated counterparts [11], it could also
aid in gauging the differentiation potential of tumor cells.
Our previous data [15] showed that DEK protein was
strongly positive in colorectal cancers and dysplastic aden-
oma of colon, but negative in adjacent normal mucosa,
demonstrating that DEK protein expression levels might
be used as a biomarker for early diagnosis of colorectal
cancers. Khodadoust et al. reported that DEK expression
levels can distinguish benign nevi from malignant mel-
anomas, indicating that this protein may prove to be highly
useful for differentiating diagnosis [19]. Additionally,
Kappes et al. investigated the localization of DEK through-
out the cell cycle and found it was always on chromatin
and as a component of mitotic chromosomes [23]. Here we
found that DEK protein is strictly located in the nucleus
of gastric cancer cells using IF and IHC staining, and
the expression level of DEK is significantly upregulated
in gastric cancer and dysplasia than in adjacent normal
gastric mucosa, indicating that DEK upregulation is an
early event in the progression of gastric cancer.
Despite the strong association between DEK expression
and cancer, reports of DEK expression-based outcome
in tumor patients are limited. Our previous study [15]
reported that high DEK expression is associated with
serosal invasion, lymph node metastasis, tumor size andte in 172 gastric cancer patients in relation to DEK protein
r disease-free (A) and overall survival (B) rates than those with
, positive; −, negative).
Figure 4 Kaplan–Meier analysis of disease-free survival and overall survival rates in 172 patients with or without DEK expressed gastric
cancer in relation to clinical stage. A–B: In the early-stage, DEK expression negatively correlated to disease-free survival and overall survival
rates, respectively. C-D: In the late-stage, the survival rates did not correlated to DEK expression.
Table 3 Cox regression model analysis of various factors
in 172 patients with gastric cancer
Characteristics B SE Wald HR 95% CI P value
Lower Upper
Univariate
Age 0.308 0.158 3.808 1.360 0.999 1.853 0.051
Gender 0.135 0.155 0.750 1.144 0.844 1.551 0.386
Tumor size 0.306 0.159 3.688 1.358 0.994 1.856 0.055
Serosal invasion 0.397 0.157 6.343 1.487 1.092 2.024 0.012*
Lauren types 0.135 0.118 1.318 1.145 0.909 1.442 0.251
Differentiation 0.219 0.116 3.584 1.245 0.992 1.561 0.058
LN metastasis 0.556 0.156 12.712 1.744 1.285 2.368 0.000**
Clinical stage 0.810 0.160 25.619 2.247 1.642 3.074 0.000**
DEK 0.455 0.160 8.111 1.576 1.152 2.155 0.004**
Multivariate
Serosal invasion 0.224 0.162 1.904 1.251 0.910 1.718 0.168
Clinical stage 0.608 0.167 13.187 1.837 1.323 2.551 0.000**
LN metastasis 0.399 0.159 6.272 1.490 1.091 2.036 0.012*
DEK 0.352 0.163 4.671 1.422 1.033 1.956 0.031*
B: coefficient; SE: standard error; Wald: Wald statistic; HR: hazard ratio;
CI: confidence interval
*P < 0.05, **P < 0.01.
Piao et al. Diagnostic Pathology 2014, 9:67 Page 6 of 7
http://www.diagnosticpathology.org/content/9/1/67differentiation, which are crucial histological features
associated with poor prognosis in colorectal cancer. Also,
DEK overexpression concomitant with any of these fea-
tures correlated with significantly lower 5-year survival
rates than those without DEK expression. Consistent with
this report, in 2013 Wang et al. revealed that acute mye-
loid leukemia patients with low DEK expression had
higher overall survival rates compared with patients with
high DEK expression [24]. Similarly, Liu et al. reported
that DEK protein showed higher expression levels in < 3-
year disease-free survival breast cancers patients than it
did in ≥3-year disease-free survival patients [21]. Here we
also found that DEK expression was strongly associated
with survival rates in early-stage tumors, and was signifi-
cantly higher in DEK low-expressed patients than in DEK
high-expressed patients. Thus, IHC examination of DEK
could be used as an additional tool to identify gastric
cancer patients at risk of malignant progression, and the
DEK expression analysis may also be useful in optimizing
individual gastric cancer therapy management, favoring
a more aggressive regimen in tumors with high DEK
expression.
Notably, many studies have reported that DEK implicated
in several signaling pathways in tumor cells and played
important role in cancer progression. Wise-Draper et al.
reported that DEK delay differentiation of keratinocyte in
a p53-independent way [25]. Wise-Draper et al. also
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tivities in a manner that influenced cellular survival
[26]. Sandén et al. reported that the DEK–NUP214 fu-
sion gene increased the proliferation of myloid cell pro-
liferation through upregulation of mTOR [27]. These data
suggested that altered DEK expression patterns might
regulate a certain signaling pathway to play an oncogenic
role in cancer development and progression. Perhaps, the
pathways regulated by DEK may represent a new strategy
for cancer therapies and further study is also required to
find out the exact signaling pathway regulated by altered
DEK in gastric cancer progression.
In conclusion, DEK overexpression appears to be associ-
ated with gastric cancer progression, and DEK may poten-
tially be used as a biomarker for prognostic evaluation and
as a therapeutic target in gastric cancer.
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